相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice
Yuka Hayakawa et al.
INVESTIGATIONAL NEW DRUGS (2022)
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
Josep M. Llovet et al.
HEPATOLOGY (2021)
The Role of the Albumin-Bilirubin Score for Predicting the Outcomes in Japanese Patients with Advanced Hepatocellular Carcinoma Treated with Ramucirumab: A Real-World Study
Takeshi Hatanaka et al.
ONCOLOGY (2021)
Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression
Atsushi Hiraoka et al.
HEPATOLOGY RESEARCH (2021)
Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
Masatoshi Kudo et al.
LIVER CANCER (2021)
Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinib
Toshifumi Tada et al.
SCIENTIFIC REPORTS (2021)
Association of Albumin-Bilirubin Grade and Sequential Treatment with Standard Systemic Therapies for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study Using a Japanese Administrative Database
Atsushi Hiraoka et al.
DRUGS-REAL WORLD OUTCOMES (2021)
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2
Masatoshi Kudo et al.
JHEP REPORTS (2021)
Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study
Changhoon Yoo et al.
LIVER CANCER (2021)
Therapeutic efficacy of lenvatinib for patients with unresectable hepatocellular carcinoma based on the middle-term outcome
Akira Fuchigami et al.
PLOS ONE (2020)
A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements
Masatoshi Kudo et al.
LIVER CANCER (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma
B. Sangro et al.
ANNALS OF ONCOLOGY (2020)
Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib
Yuwa Ando et al.
ONCOLOGY (2020)
Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of α-fetoprotein
Andrew X. Zhu et al.
LANCET ONCOLOGY (2019)
Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis
Atsushi Hiraoka et al.
CANCER MEDICINE (2019)
Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma
Atsushi Hiraoka et al.
ONCOLOGY (2019)
Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study
Masatoshi Kudo et al.
CANCERS (2019)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function
Atsushi Hiraoka et al.
LIVER CANCER (2017)
Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib
Takeshi Terashima et al.
HEPATOLOGY RESEARCH (2016)
Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma
Atsushi Hiraoka et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2016)
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach-The ALBI Grade
Philip J. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
EASL Clinical Practical Guidelines: Management of Alcoholic Liver Disease
JOURNAL OF HEPATOLOGY (2015)
Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update
Masatoshi Kudo et al.
ONCOLOGY (2014)
Investigation of the freely available easy-to-use software 'EZR' for medical statistics
Y. Kanda
BONE MARROW TRANSPLANTATION (2013)
Epidemiology of Hepatocellular Carcinoma Consider the Population
Sahil Mittal et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2013)
Imaging Study of Early Hepatocellular Carcinoma: Usefulness of Gadoxetic Acid-enhanced MR Imaging
Katsuhiro Sano et al.
RADIOLOGY (2011)
Intraindividual Comparison of Gadoxetate Disodium-enhanced MR Imaging and 64-Section Multidetector CT in the Detection of Hepatocellular Carcinoma in Patients with Cirrhosis
Michele Di Martino et al.
RADIOLOGY (2010)
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Riccardo Lencioni et al.
SEMINARS IN LIVER DISEASE (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis
Vincenzo Mazzaferro et al.
LANCET ONCOLOGY (2009)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Management of hepatoceullular carcinoma
J Bruix et al.
HEPATOLOGY (2005)
Estimating the world cancer burden: GLOBOCAN 2000
DM Parkin et al.
INTERNATIONAL JOURNAL OF CANCER (2001)